title: A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors.
abstract: A review and critical consideration of immunotherapeutical concepts in non-small cell lung cancer (NSCLC) is given. Nivolumab represents a promising option in various malignancies with more results exceeding treatment of metastatic malignant melanoma eagerly awaited.
authors: 1 Clinical Division of Oncology and Chairman, Department of Medicine I, 2 Comprehensive Cancer Center, Medical University Vienna, General Hospital, Vienna, Austria ; 3 Central European Cooperative Oncology Group, Vienna, Austria.
authors: Christoph C
authors: CC
authors: Zielinski
keywords: Immunotherapy; lung cancer; nivolumab